Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Incidence, predictive factors and preventive measures for inguinal hernia following robotic and laparoscopic radical prostatectomy: A systematic review.

Fernando MH, Garcia C, Hossack T, Ahmadi N, Thanigasalam N, Gillatt D, Leslie S, Doeuk N, Smith I, Woo HH.

J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000133. [Epub ahead of print]

PMID:
30730406
2.

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.

Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, Hamdy FC, Gillatt D, Holly J, Macefield R, Moody H, Neal DE, Walsh E, Martin RM, Metcalfe C.

Cancer Prev Res (Phila). 2018 Nov;11(11):687-696. doi: 10.1158/1940-6207.CAPR-18-0147. Epub 2018 Oct 11.

PMID:
30309839
3.

Systematic review of the safety and efficacy of osseointegration prosthesis after limb amputation.

Kunutsor SK, Gillatt D, Blom AW.

Br J Surg. 2018 Dec;105(13):1731-1741. doi: 10.1002/bjs.11005. Epub 2018 Oct 11. Review.

PMID:
30307036
4.

Is robotic radical cystectomy ready for prime time?

Patel MI, Gillatt D.

ANZ J Surg. 2018 Oct;88(10):948-949. doi: 10.1111/ans.14564. No abstract available.

PMID:
30277001
5.

A systematic review of PFE pre-prostatectomy.

Goonewardene SS, Gillatt D, Persad R.

J Robot Surg. 2018 Sep;12(3):397-400. doi: 10.1007/s11701-018-0803-8. Epub 2018 Mar 21.

PMID:
29564692
6.

Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study.

Rapport F, Hogden A, Gurney H, Gillatt D, Bierbaum M, Shih P, Churruca K.

BMJ Open. 2017 Oct 5;7(10):e017372. doi: 10.1136/bmjopen-2017-017372.

7.

Computer-assisted cystoscopy diagnosis of bladder cancer.

Gosnell ME, Polikarpov DM, Goldys EM, Zvyagin AV, Gillatt DA.

Urol Oncol. 2018 Jan;36(1):8.e9-8.e15. doi: 10.1016/j.urolonc.2017.08.026. Epub 2017 Sep 25.

PMID:
28958822
8.

Robotic radical cystectomy - revision and resection: An evolution in operative technique and platforms.

Goonewardene SS, Persad R, Gillatt D.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12578. No abstract available.

PMID:
28657209
9.

The role of enhanced recovery in open or robotic cystectomy.

Goonewardene SS, Persad R, Gillatt D.

Urol Oncol. 2017 Jun;35(6):447. doi: 10.1016/j.urolonc.2016.05.004. Epub 2017 Apr 29. No abstract available.

PMID:
28460800
10.

Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.

Chang L, Ni J, Beretov J, Wasinger VC, Hao J, Bucci J, Malouf D, Gillatt D, Graham PH, Li Y.

Sci Rep. 2017 Feb 22;7:41834. doi: 10.1038/srep41834.

11.

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Biernacka KM, Persad RA, Bahl A, Gillatt D, Holly JM, Perks CM.

Endocr Relat Cancer. 2017 Jan;24(1):17-30. Epub 2016 Oct 17.

12.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

13.

Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.

Hao J, Graham P, Chang L, Ni J, Wasinger V, Beretov J, Deng J, Duan W, Bucci J, Malouf D, Gillatt D, Li Y.

Oncotarget. 2016 Nov 8;7(45):74269-74285. doi: 10.18632/oncotarget.12368.

14.

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*.

N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14.

15.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.

16.

Erectile function post robotic radical prostatectomy: technical tips to improve outcomes?

Goonewardene SS, Persad R, Gillatt D.

J Robot Surg. 2016 Sep;10(3):267-9. doi: 10.1007/s11701-016-0578-8. Epub 2016 Jun 7. Review.

PMID:
27272758
17.

Robotic cystectomy and intracorporeal stoma formation: Robotic management of ureteric strictures.

Goonewardene SS, Persad R, Gillatt D.

Urol Oncol. 2016 Aug;34(8):375-6. doi: 10.1016/j.urolonc.2016.05.003. Epub 2016 Jun 2. No abstract available.

PMID:
27264168
18.

Robotic radical cystectomy and enhanced recovery: a new pathway.

Goonewardene SS, Persad R, Gillatt D.

World J Urol. 2016 Nov;34(11):1599-1600. Epub 2016 Mar 24. No abstract available.

PMID:
27010207
19.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial.

Hackshaw-McGeagh L, Lane JA, Persad R, Gillatt D, Holly JM, Koupparis A, Rowe E, Johnston L, Cloete J, Shiridzinomwa C, Abrams P, Penfold CM, Bahl A, Oxley J, Perks CM, Martin R.

Trials. 2016 Mar 7;17(1):123. doi: 10.1186/s13063-016-1248-x.

20.

Robotic radical cystectomy: intracorporeal versus extracorporeal versus orthotopic neobladder-Which is better?

Goonewardene SS, Persad R, Gillatt D.

World J Urol. 2016 Oct;34(10):1501-2. doi: 10.1007/s00345-016-1783-9. Epub 2016 Feb 12. No abstract available.

PMID:
26873597
21.

Cancer stem cells and signaling pathways in radioresistance.

Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, Malouf D, Gillatt D, Li Y.

Oncotarget. 2016 Mar 8;7(10):11002-17. doi: 10.18632/oncotarget.6760. Review.

22.

Penile rehabilitation for robotic radical prostatectomy: a new game.

Goonewardene SS, Persad R, Gillatt D.

J Robot Surg. 2016 Dec;10(4):379-380. Epub 2015 Dec 24. No abstract available.

PMID:
26705112
23.

Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.

Chang L, Graham P, Hao J, Bucci J, Malouf D, Gillatt D, Li Y.

Cancer Lett. 2015 Dec 28;369(2):289-97. doi: 10.1016/j.canlet.2015.09.013. Epub 2015 Sep 30. Review.

PMID:
26427840
24.

Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study.

Patel MI, Bang A, Gillatt D, Smith DP.

BJU Int. 2015 Oct;116 Suppl 3:18-25. doi: 10.1111/bju.13152. Epub 2015 Sep 2.

25.

Robot-assisted radical cystectomy with intracorporeal urinary diversion: impact on an established enhanced recovery protocol.

Koupparis A, Villeda-Sandoval C, Weale N, El-Mahdy M, Gillatt D, Rowe E.

BJU Int. 2015 Dec;116(6):924-31. doi: 10.1111/bju.13171. Epub 2015 Jul 14.

26.

Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998-2010.

Hounsome LS, Verne J, McGrath JS, Gillatt DA.

Eur Urol. 2015 Jun;67(6):1056-1062. doi: 10.1016/j.eururo.2014.12.002. Epub 2014 Dec 17.

PMID:
25530608
27.

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S.

Oncogene. 2015 Aug 13;34(33):4311-9. doi: 10.1038/onc.2014.360. Epub 2014 Nov 10.

28.

Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

Hagen RM, Adamo P, Karamat S, Oxley J, Aning JJ, Gillatt D, Persad R, Ladomery MR, Rhodes A.

Am J Clin Pathol. 2014 Oct;142(4):533-40. doi: 10.1309/AJCPH88QHXARISUP.

PMID:
25239421
29.

Cardiopulmonary reserve as determined by cardiopulmonary exercise testing correlates with length of stay and predicts complications after radical cystectomy.

Tolchard S, Angell J, Pyke M, Lewis S, Dodds N, Darweish A, White P, Gillatt D.

BJU Int. 2015 Apr;115(4):554-61. doi: 10.1111/bju.12895. Epub 2015 Jan 21.

30.

Pathological analysis of lymph nodes in anterior prostatic fat excised at robot-assisted radical prostatectomy.

Aning JJ, Thurairaja R, Gillatt DA, Koupparis AJ, Rowe EW, Oxley J.

J Clin Pathol. 2014 Sep;67(9):787-91.

PMID:
24996431
31.

The status of surgery in the management of high-risk prostate cancer.

Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, Persad R, Koupparis A.

Nat Rev Urol. 2014 Jun;11(6):342-51. doi: 10.1038/nrurol.2014.100. Epub 2014 May 13. Review.

PMID:
24818848
32.

Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study.

Redaniel MT, Martin RM, Gillatt D, Wade J, Jeffreys M.

BMC Cancer. 2013 Nov 27;13:559. doi: 10.1186/1471-2407-13-559.

33.

Nerve hyperplasia: a unique feature of ketamine cystitis.

Baker SC, Stahlschmidt J, Oxley J, Hinley J, Eardley I, Marsh F, Gillatt D, Fulford S, Southgate J.

Acta Neuropathol Commun. 2013 Oct 8;1:64. doi: 10.1186/2051-5960-1-64.

34.

The Melbourne Consensus Statement on the early detection of prostate cancer.

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ.

BJU Int. 2014 Feb;113(2):186-8. doi: 10.1111/bju.12556. Review.

35.

Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.

Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JM.

Endocr Relat Cancer. 2013 Sep 11;20(5):741-51. doi: 10.1530/ERC-13-0077. Print 2013 Oct.

PMID:
23959956
36.

When should patients with varicocoele be referred?

Aning J, Gillatt D.

Practitioner. 2012 Apr;256(1750):17-20, 2-3.

PMID:
22792685
37.

The prevalence and natural history of urinary symptoms among recreational ketamine users.

Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM.

BJU Int. 2012 Dec;110(11):1762-6. doi: 10.1111/j.1464-410X.2012.11028.x. Epub 2012 Mar 14.

38.

Managing patients with acute urinary retention.

Kuppusamy S, Gillatt D.

Practitioner. 2011 Apr;255(1739):21-3, 2-3.

PMID:
21789984
39.

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.

Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM.

Br J Cancer. 2011 May 10;104(10):1587-93. doi: 10.1038/bjc.2011.127. Epub 2011 Apr 12.

40.

Recreational ketamine: from pleasure to pain.

Wood D, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, Woodhouse C, Gillatt D.

BJU Int. 2011 Jun;107(12):1881-4. doi: 10.1111/j.1464-410X.2010.10031.x. Epub 2011 Feb 14. Review.

41.

Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells.

Astin JW, Batson J, Kadir S, Charlet J, Persad RA, Gillatt D, Oxley JD, Nobes CD.

Nat Cell Biol. 2010 Dec;12(12):1194-204. doi: 10.1038/ncb2122. Epub 2010 Nov 14.

PMID:
21076414
42.

Ketamine-associated lower urinary tract destruction: a new radiological challenge.

Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE.

Clin Radiol. 2010 Oct;65(10):795-800. doi: 10.1016/j.crad.2010.05.003. Epub 2010 Jul 29.

PMID:
20797465
43.

Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry.

McVey GP, McPhail S, Fowler S, McIntosh G, Gillatt D, Parker CC.

BJU Int. 2010 Oct;106(8):1161-4. doi: 10.1111/j.1464-410X.2010.09288.x.

44.

Diagnosing urological disorders in ageing men.

Mevcha A, Gulur DM, Gillatt D.

Practitioner. 2010 Feb;254(1726):25-6, 28-9, 2-3.

PMID:
20307027
45.

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T.

Clin Oncol (R Coll Radiol). 2010 Feb;22(1):46-55. doi: 10.1016/j.clon.2009.10.015. Epub 2009 Nov 30. Review.

PMID:
19948393
46.

Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.

Evans S, Metcalfe C, Patel B, Ibrahim F, Anson K, Chinegwundoh F, Corbishley C, Gillatt D, Kirby R, Muir G, Nargund V, Popert R, Wilson P, Persad R, Ben-Shlomo Y.

Br J Cancer. 2010 Jan 19;102(2):249-54. doi: 10.1038/sj.bjc.6605461. Epub 2009 Nov 24.

47.

Ketamine cystitis as a mimic of carcinoma in situ.

Oxley JD, Cottrell AM, Adams S, Gillatt D.

Histopathology. 2009 Dec;55(6):705-8. doi: 10.1111/j.1365-2559.2009.03437.x.

PMID:
19919587
48.

The BAUS urological cancer observatory.

Ayres BE, Gillatt DA, McPhail S, Cottrell A, Hugh Mostafid A, Fowler S, McIntosh G, Verne J, Kockelbergh R, Persad RA.

BJU Int. 2009 Aug;104(4):562. doi: 10.1111/j.1464-410X.2009.08800_1.x. No abstract available.

49.

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil.

Mevcha A, Gulur DM, Persad R, Gillatt D.

BJU Int. 2009 May;103(10):1440; author reply 1440-1. doi: 10.1111/j.1464-410X.2009.08601_1.x. No abstract available.

50.

Suspicious testicular lumps warrant urgent referral.

Mevcha A, Gillatt D.

Practitioner. 2009 Feb;253(1715):23-4, 26. No abstract available.

PMID:
19326659

Supplemental Content

Loading ...
Support Center